Title:
YOUTH - Development of an ex vivo human tumor model for the development of immunotherapies
Agreement Number:
1010568
Agreement Value:
$30,000.00
Agreement Date:
Oct 9, 2023 - Jul 1, 2024
Description:
This project aims to develop an ex vivo platform for the development of cancer immunotherapies and the discovery of predictive biomarkers. The project includes the development of protocols for 1) preserving/transporting human tumor samples and 2) maintaining the ex vivo viability of a new type of cancer.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP’s Youth Employment Program is to assist in increasing the supply of highly qualified people, promoting the benefits of advanced studies, demonstrating federal leadership by investing in the skills required to meet the needs of the knowledge economy and facilitating the transition of highly skilled young people to a rapidly changing labour market.
Location:
Montreal, Quebec, CA H3N 1Y4
Reference Number:
172-2023-2024-Q3-1010568
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
773986138
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 73 days.
Amendment Date
May 6, 2024
Recipient's Operating Name:
MisoChip
Recipient's Legal Name:
9397-2677 Québec inc.
Federal Riding Name:
Papineau
Federal Riding Number:
24055
Program:
Industrial Research Assistance Program – Youth Employment Program
Program Purpose:
The purpose of IRAP’s Youth Employment Program is to assist in increasing the supply of highly qualified people, promoting the benefits of advanced studies, demonstrating federal leadership by investing in the skills required to meet the needs of the knowledge economy and facilitating the transition of highly skilled young people to a rapidly changing labour market.
Coverage:
IRAP Youth Employment Program projects stimulate wealth creation for Canada through technological innovation.